In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

被引：42

作者：

Zeckel, ML ^{[1
]}

Preston, DA ^{[1
]}

Allen, BS ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 05期

关键词：

D O I：

10.1128/AAC.44.5.1370-1374.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro actiuitv of LY333328 was evaluated for 1,479 nosocomial gram-positive pathogens isolated in 12 countries during 1967. LY333328 MICs at which 90% of the isolates tested were inhibited for Enterococcus faecalis (n = 351), Enterococcus faecium (n = 100), Staphylococcus aureus (n = 593), coagulase-negative Staphylococcus species (n = 325), and Streptococcus pneumoniae (n = 110) were 1, 1, 2, 2, and 0.015 mu g/ml, respectively. LY333328 demonstrated potent activity against isolates of vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and penicillin-resistant pneumococci.

引用

页码：1370 / 1374

页数：5

共 24 条

[1]

[Anonymous], 1999, M100S9 NAT COMM CLIN

[2] Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci [J].

Arthur, M ;

Depardieu, F ;

Reynolds, P ;

Courvalin, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1875-1880

[3] In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide [J].

Biavasco, F ;

Vignaroli, C ;

Lupidi, R ;

Manso, E ;

Facinelli, B ;

Varaldo, PE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2165-2172

[4] Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium [J].

Caron, F ;

Gold, HS ;

Wennersten, CB ;

Farris, MG ;

Moellering, RC ;

Eliopoulos, GM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) :2749-2753

[5] Emerging resistance to antimicrobial agents in gram-positive bacteria - Enterococci, staphylococci and nonpneumococcal streptococci [J].

Cormican, MG ;

Jones, RN .

DRUGS, 1996, 51 :6-12

[6] Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci [J].

Fasola, E ;

Spangler, SK ;

Ednie, LM ;

Jacobs, MR ;

Bajaksouzian, S ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) :2661-2663

[7] Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant Gram-positive organisms [J].

Fraise, AP ;

Andrews, J ;

Wise, R .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :423-425

[8] In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates [J].

Garcia-Garrote, F ;

Cercenado, E ;

Alcala, L ;

Bouza, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2452-2455

[9] Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala [J].

Ge, M ;

Chen, Z ;

Onishi, HR ;

Kohler, J ;

Silver, LL ;

Kerns, R ;

Fukuzawa, S ;

Thompson, C ;

Kahne, D .

SCIENCE, 1999, 284 (5413) :507-511

[10] Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin [J].

Harland, S ;

Tebbs, SE ;

Elliott, TSJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (02) :273-276

← 1 2 3 →